文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

多拉韦林联合抗逆转录病毒治疗与注射/植入激素避孕在南非HIV感染女性中的药代动力学与临床关联

Pharmacokinetic and Clinical Associations Between Doravirine-Containing Antiretroviral Therapy and Injectable and Implantable Hormonal Contraceptive Methods Among Women Living With Human Immunodeficiency Virus in South Africa.
PubMed 文献 · J Infect Dis · 2025-01-01

南非约翰内斯堡前瞻性药代动力学研究,纳入128名18-45岁HIV感染女性,评估含多拉韦林ART与注射MPA、植入ENG或非激素IUD联用。未发现MPA、ENG或多拉韦林浓度显著降低,多拉韦林相关≥2级不良事件8例(3%),避孕方法相关22例(8%),ART满意度100%,研究结束时病毒抑制率86%-96%。结论认为多拉韦林与激素避孕之间无不良双向药物相互作用且不良事件少。

要点

  • 含多拉韦林ART与注射MPA或植入ENG联用未显著降低MPA、ENG或多拉韦林浓度。
  • 多拉韦林相关≥2级不良事件8例(3%),避孕方法相关22例(8%)。
  • ART满意度100%,研究结束时HIV RNA<40 copies/mL者占86%-96%。

核心结论

  • 含多拉韦林ART与注射MPA或植入ENG之间无不良双向药物相互作用,且不良事件少。

研究设计与样本

  • 5平行组前瞻性药代动力学研究,纳入南非约翰内斯堡18-45岁HIV感染女性,另设肯尼亚历史对照组为第6组。
  • 含多拉韦林ART导入≥6周后启动注射MPA、植入ENG或非激素IUD避孕,每2-4周观察12或24周。
  • 采用经验证的液相色谱-质谱法测定血清MPA、ENG及血浆多拉韦林或多替拉韦浓度。
  • 分析128名参与者,用几何均值比(90%CI)及校正年龄和BMI的多变量模型评估对数转化浓度。

主要发现

  • MPA、ENG或多拉韦林浓度均无显著降低。
  • 归因于含多拉韦林ART的≥2级不良事件8例(3%),归因于避孕方法的≥2级不良事件22例(8%)。
  • ART满意度100%,研究结束时病毒抑制(HIV RNA<40 copies/mL)范围为86%至96%。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug resistance and intolerance of dolutegravir-containing antiretroviral therapy (ART) are rising in low- and middle-income countries, resulting in a potentially increased use of doravirine-containing ART use. There are knowledge gaps regarding doravirine and hormonal contraceptive drug-drug interactions among women living with human immunodeficiency virus (HIV). METHODS: We conducted a 5-parallel-group, prospective pharmacokinetic study among women living with HIV aged 18-45 years in Johannesburg, South Africa, between November 2021 and February 2024. We included a sixth, historical comparator group from a Kenyan study. After a ≥6-week lead-in period with doravirine-containing ART, participants initiated injectable medroxyprogesterone acetate (MPA), implantable etonogestrel (ENG), or nonhormonal intrauterine device contraception and were observed every 2-4 weeks for an additional 12 or 24 weeks. We analyzed serum MPA and ENG and plasma doravirine or dolutegravir concentrations per visit, using validated liquid chromatography-mass spectrometry assays. We assessed log-transformed concentrations of each drug with geometric mean ratios (90% confidence intervals) and a multivariate model adjusted for age and body mass index. We described safety, tolerability, and effectiveness (HIV RNA <40 copies/mL) of doravirine-containing ART. RESULTS: A total of 128 participants are included in this analysis. There were no significant reductions in the MPA, ENG, or doravirine concentrations. A total of 8 (3%) adverse events grade ≥2 were considered attributable to doravirine-containing ART and 22 (8%) to the contraceptive method. ART satisfaction was 100%, and viral suppression at study exit ranged from 86% to 96%. CONCLUSIONS: We found no detrimental bidirectional drug-drug interactions and few adverse events between doravirine and hormonal contraceptives.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Patel RC, Ndlovu N, Maheria P, et al. Pharmacokinetic and Clinical Associations Between Doravirine-Containing Antiretroviral Therapy and Injectable and Implantable Hormonal Contraceptive Methods Among Women Living With Human Immunodeficiency Virus in South Africa. J Infect Dis. 2025. PMID: 40261052. doi:10.1093/infdis/jiaf196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。